newsmetry
rusign inget started
macro

HC Wainwright holds four biotech targets, cuts Palvella view

HC Wainwright kept Mineralys at a $56 target and cut Palvella to $246 from $270. Targets for Compugen, SOPHiA GENETICS and Absci were unchanged.

published
in the api
on the website

on the website stories appear 15 minutes after publication, in the api at once. connect the api →

Newsmetry newsroom

what happened

Dow Jones Newswires reported that HC Wainwright & Co. maintained price targets of $56.00 a share for Mineralys Therapeutics, $4.00 for Compugen, $14.00 for SOPHiA GENETICS and $16.00 for Absci. The firm cut its Palvella Therapeutics target to $246.00 a share from $270.00. Dow Jones Newswires cited ratings actions published by Benzinga.

TradingView said HC Wainwright & Co. also reiterated its Buy rating on Mineralys Therapeutics and kept the price target at $56.00. The target represents implied upside of 139.6% from the Oct 9 close of $23.37.

The analyst note pointed to recent AHA presentations as strengthening the clinical case for lorundrostat in cardiorenal conditions associated with dysregulated aldosterone. An FDA decision on lorundrostat is expected on December 22, 2026. TradingView said selected reference data was provided by Benzinga.

why it matters

Target revisions and the reiterated Buy rating may affect how investors assess these biotechnology stocks. For Mineralys, the cited catalysts are the clinical data and the FDA decision expected on December 22, 2026.

instruments

MLYSPVLACGENSOPHABSI

sources

  1. Mineralys Therapeutics Price Target Maintained With a $56.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 12 October 2026 at 11:44 UTC
  2. Palvella Therapeutics Price Target Cut to $246.00/Share From $270.00 by HC Wainwright & Co. — Dow Jones Newswires, 12 October 2026 at 11:41 UTC
  3. Compugen Price Target Maintained With a $4.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 12 October 2026 at 11:40 UTC
  4. SOPHiA GENETICS Price Target Maintained With a $14.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 12 October 2026 at 11:38 UTC
  5. Absci Price Target Maintained With a $16.00/Share by HC Wainwright & Co. — Dow Jones Newswires, 12 October 2026 at 11:36 UTC
  6. HC Wainwright & Co. reiterates Buy rating on Mineralys Therapeutics, $56 price target — TradingView, 12 October 2026 at 11:34 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

on the website stories appear 15 minutes after publication, in the api at once.

get stories in real time ↗

related stories